EA
SGMO

Emerald Acquisition’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Emerald Acquisition’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$101K Buy
+21,869
New +$111K ﹤0.01% 2808

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Emerald Acquisition's SGMO Position: Q3 2016 in Review

Emerald Acquisition opened a new position in SANGAMO THERAPEUTICS INC (SGMO) in Q3 2016: 21,869 shares worth $101K. The stake represents ﹤0.01% of the portfolio and ranks #2808 among its holdings.

124 funds tracked by Wall St. Rank hold SGMO as of Q3 2016.

  • Emerald Acquisition held 21,869 shares of SANGAMO THERAPEUTICS INC worth $101K as of Q3 2016.
  • SANGAMO THERAPEUTICS INC was a new Emerald Acquisition position in Q3 2016.
  • SANGAMO THERAPEUTICS INC made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #2808 holding.
  • 124 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.